News
02-10-2010, 01:21 AM
Sequenom, Inc., today announced an exclusive worldwide licensing agreement with Optherion, Inc. Under the agreement, Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM), obtained the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD).
More... (http://www.news-medical.net/news/20100210/Sequenom-CMM-licenses-rights-from-Optherion-to-develop-and-commercialize-AMD-diagnostic-tests.aspx)
More... (http://www.news-medical.net/news/20100210/Sequenom-CMM-licenses-rights-from-Optherion-to-develop-and-commercialize-AMD-diagnostic-tests.aspx)